Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain: Laboratory investigation

Journal of Neurosurgery

Volumn 114, Issue 6, 2011, Pages 1662-1671

  Oh, Seunguk ^a   Tsai, Alexander K ^a   Ohlfest, John R ^b   Panoskaltsis Mortari, Angela ^b   Vallera, Daniel A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Brain tumor; Epidermal growth factor; Glioblastoma; Pseudomonas exotoxin; Urokinase; Xenograft model

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; FIREFLY LUCIFERASE; GLUTAMYLGLYCYLPHENYLALANYLALANYLTHREONYLPHENYLALANYLLYSYLASPARTYLGLUTAMYLLEUCYL 7MUT; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; INTERMETHOD COMPARISON; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RAT; SIDE EFFECT; TUMOR XENOGRAFT; UREA NITROGEN BLOOD LEVEL;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DRUG DESIGN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDERMAL GROWTH FACTOR; GLIOBLASTOMA; HUMANS; IMMUNOTOXINS; MUTAGENESIS, SITE-DIRECTED; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, NUDE; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79957997583     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2010.11.JNS101214     Document Type: Article

References (41)

1. Benaron DA, Contag PR, Contag CH: Imaging brain structure and function, infection and gene expression in the body using light. Philos Trans R Soc Lond B Biol Sci 352:755-761, 1997 (Pubitemid 27354108)
2. Choong PF, Nadesapillai AP: Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res (415 Suppl):S46-S58, 2003 (Pubitemid 37323319)
3. Duke-Cohan JS, Morimoto C, Schlossman SF: Depletion of the helper/inducer (memory) T cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD29. Trans plantation 56:1188-1196, 1993 (Pubitemid 23348699)
4. Engebraaten O, Hjortland GO, Juell S, Hirschberg H, Fodstad O: Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals. Int J Cancer 97: 846-852, 2002 (Pubitemid 34106343)
5. Grøndahl-Hansen J, Peters HA, van Putten WL, Look MP, Pappot H, Rønne E, et al: Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1:1079-1087, 1995
6. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, et al: Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13:5144-5149, 2007 (Pubitemid 47502082)
7. Jain RK: Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 9:253-266, 1990
8. Kreitman RJ, Pastan I: Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res 58: 968-975, 1998 (Pubitemid 28182466)
9. Kunwar S: Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 88:105-111, 2003
10. Liu TF, Hall PD, Cohen KA, Willingham MC, Cai J, Thorburn A, et al: Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin Cancer Res 11:329-334, 2005 (Pubitemid 40075812)
11. Liu TF, Tatter SB, Willingham MC, Yang M, Hu JJ, Frankel AE: Growth factor receptor expression varies among high-grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. Mol Cancer Ther 2:783-787, 2003
12. Liu TF, Willingham MC, Tatter SB, Cohen KA, Lowe AC, Thorburn A, et al: Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells. Bioconjug Chem 14:1107-1114, 2003 (Pubitemid 37449037)
13. Mori T, Abe T, Wakabayashi Y, Hikawa T, Matsuo K, Yamada Y, et al: Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-a or basic fibroblast growth factor. J Neurooncol 46: 115-123, 2000 (Pubitemid 30352618)
14. Nagata S, Pastan I: Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign proteinbased therapeutics. Adv Drug Deliv Rev 61:977-985, 2009
15. Odland RM, Umeda A, Stevens S, Heinrich J, Rowe M: Reduction of tissue edema by microdialysis. Arch Otolaryngol Head Neck Surg 121:662-666, 1995
16. Oh S, Odland R, Wilson SR, Kroeger KM, Liu C, Lowenstein PR, et al: Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neu rosurg 107:568-577, 2007 (Pubitemid 47451041)
17. Oh S, Ohlfest JR, Todhunter DA, Vallera VD, Hall WA, Chen H, et al: Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery. J Neurooncol 95:331-342, 2009
18. Oh S, Stish BJ, Sachdev D, Chen H, Dudek AZ, Vallera DA: A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma. Clin Cancer Res 15:6137-6147, 2009
19. Omuro AM, Faivre S, Raymond E: Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 6:1909-1919, 2007
20. Onda M, Beers R, Xiang L, Nagata S, Wang QC, Pastan I: An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci U S A 105:11311-11316, 2008
21. Onda M, Nagata S, FitzGerald DJ, Beers R, Fisher RJ, Vincent JJ, et al: Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol 177:8822-8834, 2006 (Pubitemid 44893849)
22. Parney IF, Kunwar S, McDermott M, Berger M, Prados M, Cha S, et al: Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 102:267-275, 2005 (Pubitemid 43194076)
23. Prager GW, Breuss JM, Steurer S, Mihaly J, Binder BR: Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood 103:955-962, 2004 (Pubitemid 38129556)
24. Rainov NG, Söling A: Clinical studies with targeted toxins in malignant glioma. Rev Recent Clin Trials 1:119-131, 2006
25. Ram Z, Barnett G, Vogelbaum M, Constantini S, Lillehei K, Sherman J, et al: Pre-operative infusion of IL13-PE38QQR cytotoxin by convection-enhanced delivery (CED) in recurrent malignant glioma: a phase I/II study, in 2003 Proceedings of the American Society of Clinical Oncology Annual Meeting. Alexandria, VA: ASCO, 2003, Abstract #403
26. Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D: Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 56:1324-1330, 1996 (Pubitemid 26084349)
27. Rustamzadeh E, Hall WA, Todhunter DA, Vallera VD, Low WC, Liu H, et al: Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice. Int J Cancer 120:411-419, 2007 (Pubitemid 44956855)
28. Rustamzadeh E, Vallera DA, Todhunter DA, Low WC, Panoskaltsis-Mortari A, Hall WA: Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13. J Neurooncol 77:257-266, 2006 (Pubitemid 44404391)
29. Salajegheh M, Rudnicki A, Smith TW: Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms. Appl Immunohistochem Mol Morphol 13:184-189, 2005 (Pubitemid 40726857)
30. Schmidt M, Hynes NE, Groner B, Wels W: A bivalent singlechain antibody-toxin specific for ErbB-2 and the EGF receptor. Int J Cancer 65:538-546, 1996 (Pubitemid 26084405)
31. Shen GL, Li JL, Vitetta ES: Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing. J Immunol 152:2368-2376, 1994
32. Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortari A, Vallera DA: Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Clin Cancer Res 13:3058-3067, 2007 (Pubitemid 46849583)
33. Stish BJ, Oh S, Chen H, Dudek AZ, Kratzke RA, Vallera DA: Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity. Br J Cancer 101: 1114-1123, 2009
34. Stish BJ, Oh S, Vallera DA: Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model. J Neurooncol 87: 51-61, 2008
35. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005 (Pubitemid 40349501)
36. Todhunter DA, Hall WA, Rustamzadeh E, Shu Y, Doumbia SO, Vallera DA: A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng Des Sel 17:157-164, 2004 (Pubitemid 38477742)
37. Tsai AK, Oh S, Chen H, Shu Y, Ohlfest JR, Vallera DA: A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature. J Neurooncol [epub ahead of print], 2010
38. Vallera DA, Todhunter DA, Kuroki DW, Shu Y, Sicheneder A, Chen H: A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clin Cancer Res 11:3879-3888, 2005 (Pubitemid 40685609)
39. Vallera DA, Todhunter D, Kuroki DW, Shu Y, Sicheneder A, Panoskaltsis-Mortari A, et al: Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice. Leuk Res 29:331-341, 2005 (Pubitemid 40127061)
40. Verspaget HW, Sier CF, Ganesh S, Griffioen G, Lamers CB: Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. Eur J Cancer 31A:1105-1109, 1995
41. Vogelbaum MA, Sampson JH, Kunwar S, Chang SM, Shaffrey M, Asher AL, et al: Convection-enhanced delivery of cintredekin besudotox (interleukin-13- PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery 61:1031-1038, 2007